Learn more on this topic: Emerging Therapies for Hodgkin Lymphoma

What are the mechanisms of action and use of PD-1 inhibitors in the treatment of classical Hodgkin lymphoma?

Patrick J. Kiel, PharmD, BCPS, BCOP

Patrick J. Kiel, PharmD, BCPS, BCOP, on treating Hodgkin lymphoma.

Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.